<DOC>
	<DOCNO>NCT00321893</DOCNO>
	<brief_summary>RATIONALE : Chemoprevention use certain drug keep cancer forming , grow , come back . The use budesonide may keep lung cancer form patient lung nodule . PURPOSE : This randomized phase II trial study well inhalation budesonide work treat patient lung nodule high risk lung cancer .</brief_summary>
	<brief_title>Budesonide Treating Patients With Lung Nodules High Risk Developing Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Evaluate effect , term size number reduction compute tomography ( CT ) scan-detected undetermined lung nodule , asymptomatic subject lung nodule high-risk develop lung cancer treat inhaled budesonide v placebo . Secondary - Compare average modification nodule size nodule number due inhale budesonide versus placebo . - Correlate modulation biological marker lung cancer serum sputum treatment modification lung nodule size . - Determine treatment toxicity , side effect , safety inhale budesonide . - Evaluate role CT scan estimate grade respiratory impairment emphysema . - Determine effect inhale budesonide respiratory function treatment . OUTLINE : This randomize , double-blind , placebo control study . Participants stratify accord gender , smoke habit ( current v former smoker ) , nodule characteristic ( solid v semisolid non-solid ) . Participants randomize 1 2 treatment arm . - Arm I : Subjects receive inhale budesonide twice daily 1 year absence unacceptable toxicity . - Arm II : Subjects receive inhale placebo twice daily 1 year absence unacceptable toxicity . Participants undergo blood sputum collection periodically study biomarker correlative study . After completion study therapy , subject follow 1 month continue CT scan screening . PROJECTED ACCRUAL : A total 202 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>1 . Current smoker former smoker stop within last 15 year 2 . Smoking history &gt; 20 pack/years 3 . Age &gt; 50 year 4 . Persistent lung nodule detect Low dose compute tomography ( LDCT ) scan previous year 1 following : long diameter 4 &amp; 5 mm . Nodules may stable grown previous year ( &lt; 5 mm require additional diagnostic followup ) ; long diameter 5.1 &amp; 8 mm . Nodules may stable grown previous year . If grow , double time &gt; 1 year ; long diameter &gt; 8 mm negative PET scan , negative CT enhancement . Nodule grown double time 1 &amp; 5 year ; long diameter &gt; 8mm , non solid partially solid nodule , stable grown double time 1 &amp; 5 year 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; 1 ( Karnofsky &gt; 60 % ) 6 . Participants must normal organ marrow function define : Leukocytes &gt; 3,000/mL , absolute neutrophil count great 1,500/mL , platelet great 100,000/mL , total bilirubin lower 1.5 * upper normal institutional limit , aspartate aminotransferase ( AST SGOT ) /alanine aminotransferase ( ALT SGPT ) low 1.5 * upper normal institutional limit , creatinine low 1.5 * upper normal institutional limit 7 . Females must postmenopausal ( ie , least 1 year pass last menstruation ) , surgically sterile , use acceptable contraceptive measure judge Investigator . ( A fertile woman define childbearing potential , first menstruation 1 year last menstruation. ) . Negative serum betaHCG woman childbearing potential require baseline . Should woman become pregnant suspect pregnant participating study , inform study physician immediately 8 . Ability understand willingness sign write informed consent document . 1 . More 6 lung nodule ( suspect chronic granulomatous disease ) 2 . Lung nodules clearly benign morphological feature CT scan ( i.e , homogenous calcification , solid nodule regular round polygonal margin distance pleura &lt; 1cm ) 3 . Subjects currently suffer malignant disease malignant disease within last 5 year except cervical carcinoma situ non melanoma skin cancer 4 . Regular/chronic use oral inhaled corticosteroid ; regular use define total 3 month cumulative use last 12 month 5 . Use investigational agent time enrollment study three month precede study enrollment 6 . History allergic reaction attribute compound similar chemical biologic composition corticosteroid 7 . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . Any factor investigator 's discretion contraindicate use inhaled corticosteroid 8 . Pregnant lactating female , female plan become pregnant study . Should woman become pregnant suspect pregnant participating study , inform study physician immediately . If need , pregnancy test perform serum baseline lab test 9 . HIVpositive patient immunodeficiency exclude risk infection</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Small cell lung cancer</keyword>
	<keyword>Non-small cell lung cancer</keyword>
	<keyword>Budesonide</keyword>
	<keyword>Entocort EC</keyword>
	<keyword>Pulmicort Respules</keyword>
	<keyword>Rhinocort aqua</keyword>
	<keyword>Aerosol budesonide treatment</keyword>
	<keyword>Smoking</keyword>
</DOC>